Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Board Changes

26 Mar 2013 16:19

RNS Number : 9352A
Plant Health Care PLC
26 March 2013
 



 

26 March 2013

 

Plant Health Care plc

("Plant Health Care" or "the Company")

Board Changes 

Plant Health Care plc, ("PHC"),a leading provider of novel patent protected biological products to the global agriculture markets, is today announcing the appointment of a new Chief Executive Officer, among other Board changes.

 

After twelve years as CEO of Plant Health Care, John Brady will be stepping down on 2 April 2013. He will be succeeded by Paul Schmidt who will take over as CEO the same day.

 

John has provided outstanding leadership of the Company and the Board would like to pay tribute to his enormous contribution. The Board is delighted that the Company is retaining John's services as a non-executive director, in which role the Company will continue to benefit from his invaluable experience.

 

The Company is pleased to welcome Paul Schmidt. Mr Schmidt has extensive operational experience in the agriculture industry, having served in senior roles in the USA, Germany and Canada during 25 years with Bayer CropScience and its predecessor companies. As President of Merck/EMD Crop Bioscience, a leading developer of natural plant health products, Paul led a turn-around which resulted in substantially increased sales and profit. In February 2011, he oversaw the sale of the business to Novozymes for $275 million. Paul graduated from the University of Saskatchewan with a BSA in Agronomy in 1980.

 

Sam Wauchope, having served as a non-executive director for nine years, four of them as Senior Independent Director, will step down from the Board on 2 April 2013. The Board would like to thank Sam for the contribution he has made to the Company.

 

Michael Higgins will join the Company as the Senior Independent Director and Chair of the Audit Committee following the Company's AGM on 9 May 2013. He is currently non-executive Chairman of AIM quoted Ebiquity plc and Deputy Chairman of the Quoted Companies Alliance. Michael also works with, and invests in, a number of early-stage businesses. Michael was a Senior Adviser at KPMG following ten years as a Partner. Prior to KPMG, he was a Director at Charterhouse Bank, worked at Saudi International Bank and qualified as an accountant with Price Waterhouse (now PricewaterhouseCoopers).

 

Dr. Christopher Richards, Chairman commented: "I wish to place on record our appreciation of all that John has done for Plant Health Care; this Company is very much his personal creation. I am delighted that we are retaining John's services as a non-executive director, in which role we will continue to benefit from his invaluable experience. I would also like to take this opportunity to pay tribute to Sam for his contribution, which included a stint as Interim Chairman in 2012.

 

"Securing the services of Paul Schmidt as the Company's new CEO is a real coup. Paul's extensive experience in the industry leaves us very well positioned to progress to the next stage in the Company's development. I am convinced that Paul has the right qualities to lead Plant Health Care to this next level. We look forward to welcoming Michael to the Company and to the Board following our AGM. Michael will bring a wealth of additional experience that we will benefit from."

 

 

- ENDS -

 

About Plant Health Care plc: Plant Health Care plc ("Plant Health Care") is a leading provider of novel patent protected biological products to the global agriculture markets. The Company's ordinary shares have been quoted on the AIM Market of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") since February 2010 (ticker symbol/mnemonic: PHC).

Further information is available at: www.planthealthcare.com.

 

 For further information, please contact:

Plant Health Care plc

 

 

Dr Christopher Richards, Chairman

On the day Tel: +44 (0) 20 7250 1446

John Brady, Chief Executive Officer

On the day Tel: +44 (0) 20 7250 1446

Thereafter: Tel: +1-603-525-3702 

Stephen Weaver, Finance Director

Tel: +1-412-826-5488 x151

 

Nomura Code Securities

Chris Collins / Clare Terlouw / Chris Golden

Tel: +44 (0) 20 7776 1200

Powerscourt

Paul Durman / Nick Dibden / Sophie Moate

Tel: +44 (0) 20 7250 1446

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAJFMFTMBBTBJJ
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.